Associated Papers
Real-World Evidence of the Prevalence of Driver Mutations in Anorectal Melanoma.
Jutten E et al.
Molecular Diagnosis & Therapy, 2025
Gastrointestinal Stromal Tumors Mimicking Gynecologic Disease: Clinicopathological Analysis of 20 Cases.
Liu Y et al.
Diagnostics (basel, Switzerland), 2022
Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
Muñoz-González JI et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 2021
A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Zhou Y et al.
Cancer Medicine, 2020
Phase and context shape the function of composite oncogenic mutations.
Gorelick AN et al.
Nature, 2020
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
Banks E et al.
Science Translational Medicine, 2020
Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J et al.
Pathology Oncology Research : Por, 2020
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy.
Mühlenberg T et al.
Molecular Cancer Therapeutics, 2019
Targeted Genomic Profiling of Acral Melanoma.
Yeh I et al.
Journal of the National Cancer Institute, 2019
Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs).
Yu K et al.
Oncotarget, 2017
Stem cell factor receptor/c-Kit: from basic science to clinical implications.
Lennartsson J et al.
Physiological Reviews, 2012
Large-scale analysis of KIT aberrations in Chinese patients with melanoma.
Kong Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.
Roberts KG et al.
Cancer Research, 2010
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
Lasota J et al.
Histopathology, 2008
Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the 'second hit' hypothesis.
Becker H et al.
Leukemia, 2008